Translational human gut microbiome research: What are the missing pieces of the puzzle? Authors: Marina Fassarella, Hauke Smidt Published: 2026 ABSTRACT AbstractBackgroundHuman gut microbiome research has expanded remarkably over the past two decades, revealing the fundamental role of gut microbes in human health and disease. Despite these advances, translation into evidence-based clinical practice and public health implementation remains exceptionally limited. This integrative translational perspective review evaluates human gut microbiome research across four critical aspects: translational successes, barriers to effective translation, applicability of frameworks from other medical disciplines, and strategies to enhance translational progress.Main textHuman gut microbiome research was evaluated through the lens of translational medical research principles, as summarised below. (1) Translational successes in human gut microbiome research are explored by analysing the developmental pathways of major microbiome-based or microbiome-targeted approaches, including faecal microbiota transplantation, probiotics, postbiotics, prebiotics, and dietary interventions, despite overall limited clinical and public health translation. (2) Established translational medical research frameworks served as a foundation to identify missing elements in current human gut microbiome research, including progression through T0–T4 phases, bidirectional knowledge flow, prioritization of unmet patient and societal health needs, patient-centric approaches, stakeholder engagement, and interdisciplinary collaboration. Integration of these principles is discussed in light of the specific characteristics, challenges, and limitations of human gut microbiome research. (3) Translational barriers in human gut microbiome research were analysed beyond limited integration of translational medical principles. These arise from the inherent complexity and high-dimensional nature of the gut microbiome, temporal and inter-individual variability, confounding factors, inconsistent methodological standardization and validation, and fragmentation across research efforts. Collectively, these barriers hinder causal inference, resulting in a low-quality evidence base and limiting effective translation. (4) A framework to advance translational human gut microbiome research is proposed based on the previous findings, including strategic priorities such as education and training in translational research principles for gut microbiome researchers. ConclusionsHuman gut microbiome research remains largely confined to early translational phases, with progression toward effective translation limited by intrinsic and methodological barriers that hinder causal inference and high-level evidence generation. Integration of core translational medical research principles offers a pathway to bridge these gaps, with education and training of gut microbiome researchers emerging as a key priority for advancing translational progress.Supplementary informationThe online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08490-7.Keywords: Human gut microbiome, Translational medical research, T0-T4 Translational research, Unmet health needs, Patient-centric research, Stakeholder engagement, Interdisciplinary collaboration, Translational research education Introduction Human gut microbiome research has advanced substantially over the past two decades, driven by growing evidence of the critical role of gut microbes in human health and disease [1]. The gut microbiome is increasingly recognized as a key contributor to host physiology, mediating immune development, nutrient production, food digestion, metabolic homeostasis, and brain function [2]. Consistent with these processes, alterations in gut microbiota composition and activity have been associated with a broad range of clinical conditions, including, but not limited to, autoimmune diseases, obesity and metabolic syndrome, inflammatory bowel disease, cancer, and depression [3]. Despite this well-established physiological and clinical relevance, human gut microbiome research is characterized by a central paradox. From one perspective, state-of-the-art methodologies, advanced statistical tools, a rapidly expanding body of large-scale datasets and published studies are readily accessible through the research literature [4]. From a contrasting perspective, the translation of human gut microbiome research into clinical practice and public health remains in its early stages, with only a few notable exceptions, highlighting a persistent gap between the current evidence base and real-world implementation [5]. One of the major challenges in human gut microbiome research is to move from association to causation, fundamental to support strong evidence for practical application of findings [6–8]. Contributing to this challenge are the high diversity and intrinsic complexity of the gut ecosystem, populated by a thousand microbial species, including bacteria, archaea, fungi and viruses, interacting among themselves and with the host [9]. Furthermore, the characteristics of the human gut microbiome are highly individual-specific, shaped not only by host genetics, but also by environmental factors, such as mode of birth, age, medication, diet, and lifestyle overall [10, 11]. As a result, there is no consensus about the definition of a ‘healthy gut microbiome’, which is partly attributed to its inter-individual and temporal variability [12, 13]. Collectively, these challenges have been widely recognised and extensively discussed in the research literature, with numerous strategies and methodological improvements proposed to address them. In line with that, human gut microbiome research is supported by established frameworks that emphasize characterization of the gut ecosystem, inference of causal relationships between microbiota composition with health and disease, methodological advances including protocol standardization and data integration, as well as evolving regulatory aspects, while presenting limited translational considerations [4, 14–20]. In parallel, translational medical research frameworks are based in core principles such as prioritization of unmet health needs, patient-centric approaches, stakeholder engagement and interdisciplinary collaboration, with the aim to facilitate the progress of research discoveries to benefit human health [21–28]. These two domains have evolved independently, resulting in a notable research gap: human gut microbiome research remains predominantly biologically oriented, with limited integration of translational medical research principles, while translational frameworks have yet to be systematically adapted to the inherent complexity, high dimensionality, and temporal variability of the human gut microbiome. In this review, we present a preliminary conceptual and methodological synthesis as a step toward integrating these two domains: human gut microbiome research and translational medical research. In addition to identifying and discussing critical conceptual and practical challenges, we propose actionable priorities and concrete steps to advance translation in human gut microbiome research. Table 1 summarizes the key terms and definitions used in this review and supports the subsequent discussion of both domains. Table 1Key terms and definitions used in this reviewTerminologyDefinitionTranslational Medical ResearchBiomarkerAn objective and quantifiable measure of a physiological process, pathological process or response to an exposure, intervention or treatment [29].Biomarker validationFrameworks [29, 30]:• Analytical validity: The ability of a test to accurately and reliably measure the intended biological signal, with appropriate precision, sensitivity, specificity, and reproducibility under laboratory conditions.• Clinical validity: The extent to which a biological signal or test result is associated with a clinically relevant condition or outcome in humans, including its ability to distinguish or predict disease presence, prognosis, or related clinical states.• Clinical utility: The extent to which use of a test improves clinical decision-making and patient outcomes, including its impact on diagnosis, prevention, treatment, or disease management.• Ethical, legal, and social implications: The extent to which the development and use of a test raises ethical, legal, and social considerations, including issues related to consent, privacy, data use, equity, and potential misuse.ConfounderA pre-exposure variable that is associated with both the exposure and the outcome and is not part of the causal pathway from exposure to outcome [31].EndpointA variable intended to reflect the effect of an intervention and is used as a basis for the statistical evaluation of treatment efficacy or safety. In patient-centric research, endpoints may also include characteristics or variables that reflect how a patient feels, functions, or survives [32].Evidence-based clinical practiceIntegration of the best research evidence with clinical expertise, incorporating the values and preferences of the patient, in a shared decision-making process, within a patient-centric approach [33].Health guidelineA document issued under agency authority that contains recommendations for clinical practice or public health policy, describing a specific prevention, treatment, or policy action. The scientific evidence underlying these statements is typically obtained through the systematic review of the literature and organized in evidence summaries [34].Human healthA state of complete physical, mental and social well-being and not merely the absence of disease or infirmity [35].ImplementationRefers to the integration and sustained adoption of evidence-based interventions or processes into routine clinical practice and public health systems to improve real-world health outcomes [36, 37].Interdisciplinary researchA mode of research by teams or individuals that integrates information, data, techniques, tools, perspectives, concepts, and/or theories from two or more disciplines or bodies of specialized knowledge, to advance fundamental understanding or to solve problems whose solutions are beyond the scope of a single discipline or area of research practice [38, 39].Levels of evidenceA hierarchy of studies to guide the decision on the best evidence [40]:• Level 1 – highest quality evidence: based on systematic reviews of randomized controlled trials, or high-quality individual trials. Considered the most reliable as they minimize bias and combine multiple studies.• Level 2 – moderate to high quality: based on cohort studies (following groups over time), or lower quality randomized controlled trials. Reliable for studying risk factors and outcomes, however, more prone to bias than randomized controlled trials.• Level 3 – Moderate quality: based on case-control studies. Useful for rare conditions, however, offer higher risk of bias.• Level 4 – Low quality: based on case series and case reports of observations without control groups. Offer limited ability to infer causality.• Level 5 – Lowest quality: based on expert opinion, mechanism-based reasoning. No direct research evidence is available, offering the highest risk of bias.Patient-centric researchAn approach to designing and conducting research that prioritizes the needs, preferences, and lived experiences of patients, actively involves them as co-creators in the research process, and aims to generate outcomes that are meaningful at the individual patient level [41, 42].Public healthThe art and science of preventing disease, prolonging life and promoting health through the organized efforts of society [43].Public health policyThe set of laws, regulations, decisions, and organizational practices that influence population health conditions, informed by the best available scientific, contextual, and implementation evidence to improve health outcomes [44].StakeholdersIndividuals or groups responsible for or affected by research outcomes [45].Translational barriersRegulatory, financial, infrastructural, workforce-related, ethical, healthcare system, and patient- and population-level factors, including acceptance, engagement, and equity considerations, that impede the efficient translation of biomedical discoveries into clinical practice or public health [37].Translational medical researchor translational medicineAn interdisciplinary branch of the biomedical field supported by three main pillars: bench-side, bedside and community, with the goal to combine disciplines, resources, expertise, and techniques within these pillars to promote enhancements in prevention, diagnosis, and therapies [46].(21st) Twenty-first-century skillsCompetencies often referred to as soft skills, needed to engage effectively in modern society, organized into four domains [47]:• Ways of Thinking–Creativity and innovation–Critical thinking, problem solving, decision making–Learning to learn, metacognition• Ways of Working– Communication– Collaboration (teamwork)• Tools for Working– Information literacy (includes research on sources, evidence, biases, etc.)– Digital technologies literacy• Living in the World– Citizenship – local and global– Life and career– Personal and social responsibility – including cultural awareness and competenceUnmet needs• Unmet health need: refers to the gap between an individual’s or population’s current health status and a state of optimal health. This concept encompasses biological, environmental, and behavioural determinants of health [48]. (Used in this review as a broad term, representing all the other dimensions of unmet needs described below, where applicable).• Unmet healthcare need: refers to the requirement for health services, interventions, or resources to maintain, restore, or improve health status [19]• Unmet clinical need: refers to the requirement for diagnosis, treatment, or management of a specific disease or condition at the individual level [28, 49].• Unmet medical need: refers to a condition for which there is currently no satisfactory method of prevention, diagnosis, or treatment, or where existing interventions are insufficient in effectiveness, safety, or accessibility [50].Human gut microbiomeBacteriophage therapyA therapy based on the use of bacteriophages (viruses) to selectively infect and lyse specific bacterial populations within the human gut microbiome [51].Gut health(general)A state of normal gastrointestinal function without active gastrointestinal disease and gut-related symptoms that affect quality of life [13].Healthy state(gut microbiome)A health-associated state, characterised by a high microbial diversity, which favours functional diversity and microbe–microbe and host–microbe interactions. Also referred as equilibrium state, balanced state or homeostatic state [9].Human gut microbiomeThe entire gut ecosystem, including all the microorganisms (bacteria, archaea, lower and higher eukaryotes, as well as viruses), their genomes, associated functions and actual activity and the surrounding environmental conditions [52].Human gut microbiotaCollection of microorganisms present in the gut environment [52].Faecal microbiota transplantationTransfer of faeces suspension from a ‘healthy’ donor to a recipient who harbours an altered gut microbiota associated with disease [53].PrebioticA substrate that is selectively utilised by host microorganisms conferring a health benefit [54].PostbioticPreparation of inanimate microbes and/or their components that confers a health benefit on the host [55].ProbioticLive microorganisms that, when administered in adequate amounts, confer a health benefit on the host [54].Unhealthy state(gut microbiome)Ecosystem often characterised by a low microbial diversity, with a depletion of health- associated microbes and expansion of pathogens; state associated with disease, also called dysbiosis [9].Translational human gut microbiome researchInterventions, therapies, or diagnostics• Gut microbiome-based: approaches in which the gut microbiome serves as the foundation, data source, or biological material used to develop diagnostics, therapeutics, or other interventions, rather than being the direct target of modification [56].• Gut microbiome-targeted: approaches aimed at directly modifying the composition, structure, or function of the gut microbiome, where the microbiome is the primary therapeutic target. They can also be gut microbiome-based [57].Personalized medicine or nutritionAn approach that tailors treatment or dietary interventions to individuals based on clinical, environmental, and lifestyle factors, and that may include gut microbiome–derived data [58, 59].Precision medicineAn approach that aims to improve the prediction of the most effective treatment for individual patients by integrating mechanistic insights from multi-omics and clinical data, potentially including gut microbiome–derived data [60].Translational human gut microbiome researchThe extension and application of the principles of translational medical research to human gut microbiome research, with adjustments to address the complex nature of the gut ecosystem and its inherent challenges and methodological limitations (this review).Translational human gut microbiome researcherA researcher who applies and extends the principles of translational medical research to human gut microbiome research, integrating basic and clinical perspectives, bridging disciplinary boundaries, and facilitating connections among stakeholders to achieve effective translation (this review). Key terms and definitions used in this review Frameworks [29, 30]: • Analytical validity: The ability of a test to accurately and reliably measure the intended biological signal, with appropriate precision, sensitivity, specificity, and reproducibility under laboratory conditions. • Clinical validity: The extent to which a biological signal or test result is associated with a clinically relevant condition or outcome in humans, including its ability to distinguish or predict disease presence, prognosis, or related clinical states. • Clinical utility: The extent to which use of a test improves clinical decision-making and patient outcomes, including its impact on diagnosis, prevention, treatment, or disease management. • Ethical, legal, and social implications: The extent to which the development and use of a test raises ethical, legal, and social considerations, including issues related to consent, privacy, data use, equity, and potential misuse. A hierarchy of studies to guide the decision on the best evidence [40]: • Level 1 – highest quality evidence: based on systematic reviews of randomized controlled trials, or high-quality individual trials. Considered the most reliable as they minimize bias and combine multiple studies. • Level 2 – moderate to high quality: based on cohort studies (following groups over time), or lower quality randomized controlled trials. Reliable for studying risk factors and outcomes, however, more prone to bias than randomized controlled trials. • Level 3 – Moderate quality: based on case-control studies. Useful for rare conditions, however, offer higher risk of bias. • Level 4 – Low quality: based on case series and case reports of observations without control groups. Offer limited ability to infer causality. • Level 5 – Lowest quality: based on expert opinion, mechanism-based reasoning. No direct research evidence is available, offering the highest risk of bias. Translational medical research or translational medicine Competencies often referred to as soft skills, needed to engage effectively in modern society, organized into four domains [47]: • Ways of Thinking –Creativity and innovation –Critical thinking, problem solving, decision making –Learning to learn, metacognition • Ways of Working – Communication – Collaboration (teamwork) • Tools for Working – Information literacy (includes research on sources, evidence, biases, etc.) – Digital technologies literacy • Living in the World – Citizenship – local and global – Life and career – Personal and social responsibility – including cultural awareness and competence • Unmet health need: refers to the gap between an individual’s or population’s current health status and a state of optimal health. This concept encompasses biological, environmental, and behavioural determinants of health [48]. (Used in this review as a broad term, representing all the other dimensions of unmet needs described below, where applicable). • Unmet healthcare need: refers to the requirement for health services, interventions, or resources to maintain, restore, or improve health status [19] • Unmet clinical need: refers to the requirement for diagnosis, treatment, or management of a specific disease or condition at the individual level [28, 49]. • Unmet medical need: refers to a condition for which there is currently no satisfactory method of prevention, diagnosis, or treatment, or where existing interventions are insufficient in effectiveness, safety, or accessibility [50]. Gut health (general) Healthy state (gut microbiome) Unhealthy state (gut microbiome) • Gut microbiome-based: approaches in which the gut microbiome serves as the foundation, data source, or biological material used to develop diagnostics, therapeutics, or other interventions, rather than being the direct target of modification [56]. • Gut microbiome-targeted: approaches aimed at directly modifying the composition, structure, or function of the gut microbiome, where the microbiome is the primary therapeutic target. They can also be gut microbiome-based [57]. Methods This is an integrative translational perspective review guided by four conceptual aspects addressing: (I) translational successes in human gut microbiome research, (II) barriers to translation, (III) translational frameworks in other medical fields, and (IV) their applicability to microbiome research. A targeted, non-exhaustive, iterative literature search was conducted, in which emerging insights informed subsequent refinement of the conceptual scope and search focus. Searches were performed in PubMed, Medline, and Google Scholar, supplemented by regulatory agency sources and backward and forward citation tracking. Detailed information on the search strategy, including search terms, selection criteria, and methodological considerations, is provided in Supplementary Methods 1. We systematically screened major categories of interventions based on or targeting the human gut microbiome, including probiotics, prebiotics, postbiotics, bacteriophages, faecal microbiota transplantation (FMT), and dietary interventions. For each category, we identified representative examples of successful translation, either clinical or populational. “Success” was defined as the achievement of a regulatory pathway (for example, formal approval or regulatory allowance), demonstration of clinical efficacy in human studies, and evidence of real-world implementation (for example, guideline inclusion or extensive clinical use). Where applicable, we selected the earliest example meeting these criteria to illustrate first-in-class translation within each category. Methodological details of this screening are provided in Supplementary Methods 2. Translational medical research Translational medical research or translational medicine is defined by the European Society for Translational Medicine (2015) as an interdisciplinary branch of the biomedical field supported by three main pillars: bench-side, bedside and community, with the goal to combine disciplines, resources, expertise, and techniques within these pillars to promote enhancements in prevention, diagnosis, and therapies [46]. According to the National Center for Advancing Translational Sciences (2025), translational medical research is guided by seven core principles aimed at accelerating the translation of scientific discoveries into improved health outcomes [27]. These include prioritizing research that addresses unmet patient and population health needs; fostering creativity and innovation in research design and implementation; developing generalizable solutions to persistent challenges in translational research across diseases and settings; leveraging cross-disciplinary team science; enhancing the efficiency and speed of translational processes through methodological and operational innovations; promoting partnerships across disciplines, sectors, patients, and communities; and ensuring that research is conducted using bold, rigorous, and reproducible approaches that strengthen the reliability and impact of findings. Furthermore, translational medical research is characterized by bidirectional knowledge flow across five defined translational phases (T0–T4), which support the progression of research from basic discovery to population-level health impact. These phases are summarized as follows [61]: T0—Basic research, preclinical studies, and animal models: Mechanistic and exploratory studies aimed at identifying biological pathways, disease mechanisms, biomarkers, and potential therapeutic targets. T0—Basic research, preclinical studies, and animal models: Mechanistic and exploratory studies aimed at identifying biological pathways, disease mechanisms, biomarkers, and potential therapeutic targets. T1—Translation to humans: Proof-of-concept or Phase I clinical trials assessing safety, tolerability, pharmacodynamics, and early efficacy in small human cohorts. T1—Translation to humans: Proof-of-concept or Phase I clinical trials assessing safety, tolerability, pharmacodynamics, and early efficacy in small human cohorts. T2—Clinical validation: Phase II and III controlled clinical trials evaluating efficacy, safety, dosing, and comparative effectiveness against standard-of-care interventions in pilot studies, followed by larger patient populations. T2—Clinical validation: Phase II and III controlled clinical trials evaluating efficacy, safety, dosing, and comparative effectiveness against standard-of-care interventions in pilot studies, followed by larger patient populations. T3—Clinical translation: Evidence-based clinical practice, focused on adoption, integration, and optimization of interventions, diagnostics and protocols within clinical guidelines and routine healthcare systems. T3—Clinical translation: Evidence-based clinical practice, focused on adoption, integration, and optimization of interventions, diagnostics and protocols within clinical guidelines and routine healthcare systems. T4—Society translation: Population-level health outcomes and epidemiological impact, including preventive strategies, public health guidelines, and policy interventions aimed at improving long-term health. T4—Society translation: Population-level health outcomes and epidemiological impact, including preventive strategies, public health guidelines, and policy interventions aimed at improving long-term health. Fundamentally, translational medical research starts with basic research and preclinical studies (T0), progresses through the clinical phases (T1–T2), and ultimately achieves the later phases focused on effective translation at the clinical (T3), or populational and societal levels (T4) [62]. These operational phases of translational medical research are not strictly linear but are instead characterized by iterative feedback loops involving continuous cycles of data collection, analysis, dissemination, and stakeholder engagement across all stages [22, 63]. This bidirectional exchange of information ensures that research activities remain aligned with patient and population health needs, while insights from clinical practice and real-world settings can in turn inform basic and preclinical research [64, 65]. Consequently, the effectiveness of translational medical research depends on an integrated and responsive research infrastructure that supports rapid bidirectional learning across systems, in which evidence generation and clinical practice are continuously interconnected to improve the implementation of research outcomes [26, 36, 66]. A key challenge in this process is surpassing the “Valley of Death”, which in this context refers to the failure of promising studies to progress meaningfully toward effective translation [49, 67]. Successful translation in human gut microbiome research Translation in human gut microbiome research encompasses the development, clinical validation, regulatory approval and real-world implementation of interventions based on or targeting the human gut microbiome, as well as biomarkers and diagnostic tools for disease stratification, prognosis, and prediction of treatment response [15, 57, 68, 69]. Extensively explored categories of such interventions include supplementation of probiotics, prebiotics, and postbiotics, therapies with bacteriophages, or more extensive therapies with antibiotics or FMT [51, 55, 70, 71]. They also include dietary interventions, nutritional recommendations and health advice for both clinical practice and population-level guidance [72, 73]. Successful translation can be defined as the fulfilment of at least one of the following criteria: achievement of a regulatory pathway (for example, approval or formal regulatory allowance by agencies such as the European Medicines Agency), inclusion in clinical practice guidelines (for example, by the European Society for Clinical Nutrition and Metabolism), evidence of extensive clinical implementation, or integration into public health recommendations and policies (for example, by the World Health Organization) [5, 15, 19]. In Table 2 (Part A), types of human gut microbiome studies are classified according to translational medical research phases [61, 62]. Current evidence indicates that most human gut microbiome research to date is classified within T0 (basic research and preclinical studies), T1 (translation to humans: proof-of-concept studies) and T2/II (validation: pilot clinical studies), while progressively moving toward the later clinical phase T2/III (validation: larger clinical studies) [1, 3, 5]. Table 2Translational human gut microbiome research: phases and successful applications Translational human gut microbiome research: phases and successful applications Table 2 (Part B) presents illustrative successful cases of effective translation within the gut microbiome field, highlighting pioneering and influential studies across different phases of research. These examples demonstrate the diverse translational pathways that can be followed, not necessarily traversing all translational phases in a fixed sequence, but instead involving iterative feedback loops with interdependent stages across T0–T4. Among all intervention categories, FMT represents the most advanced example of clinical translation in human gut microbiome research. In particular, FMT for recurrent Clostridioides difficile infection has demonstrated high clinical efficacy, achieved guideline endorsement, and progressed through regulated clinical use guidelines, establishing it as a landmark case of therapeutic implementation [53, 71, 74–76]. Despite this progress, methodological refinements, including the optimisation of delivery routes, donor selection, and product standardisation, remain active areas of development, together with the surge of defined microbial consortia and other live biotherapeutic products as alternatives to donor-derived faecal material [5, 94, 95]. Within defined microbial therapeutics, probiotic interventions represent an earlier but well-established translational category [55]. A key example is Lactobacillus rhamnosus GG, as a landmark strain which has accumulated extensive clinical evidence supporting its use in gastrointestinal and infectious disease contexts and has become one of the most widely studied and clinically applied probiotic strains [77–81]. Postbiotic interventions remain in a more recent stage of translation, with pasteurised Akkermansia muciniphila representing an early example of clinical development, supported by a preliminary proof-of-concept study demonstrating safety and metabolic effects, followed by a pilot randomized controlled trial reporting weight loss maintenance in overweight and obesity, although regulatory pathways and large-scale implementation are still emerging [85–88]. The simplification of this specific process was supported by the fact that A. muciniphila is a common inhabitant of the human gut [96]. Prebiotic interventions are exemplified by inulin, the first clinically validated prebiotic with health claims [93]. Inulin supplementation represents an established intervention with demonstrated selective effects on gut microbial composition and gut function, although it remains primarily regulated as food ingredient rather than therapeutic agent [89–92]. Dietary interventions constitute a distinct translational category in which gut microbiome relevance has predominantly been established retrospectively rather than as an original design principle. For example, the low-FODMAP diet (FODMAP: fermentable oligosaccharides, disaccharides, monosaccharides and polyols) represents a clinically derived dietary intervention originally developed for the management of gastrointestinal symptoms in irritable bowel syndrome and only later associated with gut microbiome-related mechanisms [73]. Another example is the Mediterranean diet, which originated in traditional dietary practices and was later associated with gut microbiome-mediated mechanisms contributing to its cardiometabolic and anti-inflammatory health benefits [97]. Finally, several intervention categories remain in the early phases of translational development (T0–T2), including bacteriophage-based therapies, next-generation probiotic strains, and novel prebiotic compounds, which are currently under active investigation but have not yet achieved robust clinical evidence to support effective translation [1, 3, 5, 15]. The same applies to microbiome-based biomarkers of health and disease, as well as predictive tools for precision medicine [57, 68]. Translational human gut microbiome research: a complex puzzle Given the limited progress in translating human gut microbiome research into clinical practice and public health, we compared current research frameworks applied in this field [4, 14–20] with those in translational medical research [21–28], to identify key missing elements for effective translation. These elements were organized and are represented here as an incomplete puzzle, with some pieces yet to be identified (Fig. 1). The “pieces of the puzzle” analogy highlights the interdependence of all components in translational human gut microbiome research, where the absence of any single element may compromise overall success. Translational human gut microbiome research: identifying the missing pieces. By exploring translational medical research frameworks, we identified several elements that may support the advancement of translational human gut microbiome research. Central to this is a patient-centric approach, together with stakeholder engagement and interdisciplinary collaboration across diverse domains. Progress through the translational phases (T0–T4), with a focus on unmet patient and societal health needs, may support the generation of robust evidence for regulatory approval and implementation. To integrate these core principles into human gut microbiome research, specialized education and training may represent a promising step. Blank puzzle pieces represent additional yet unknown elements and invite readers to reflect on other potentially missing pieces for future integration Building on this simplified representation of missing elements, the following sections present and discuss core principles of translational medical research with a focus on their integration to human gut microbiome research. Translational human gut microbiome researcher A fundamental distinctive characteristic of a translational researcher is a comprehensive perspective with both research domain expertise and holistic understanding, which enables interdisciplinary research design, intentionally advancing the translational process [98, 99]. In particular, the ability to translate human gut microbiome knowledge into real-world health impact requires specialized education, encompassing disciplines within basic microbiology, gut microbiome, research methods, human health, and translational medical research, with the integration of fundamental 21st century skills (as defined in Table 1) [47, 100]. In line with that, Fig. 2 presents a proposed curriculum for the education of translational human gut microbiome researchers, with the purpose to serve as a foundation for further refinement. Proposed fundamental curriculum for the education of translational human gut microbiome researchers. The extensive knowledge required to understand the complexity of human gut microbiome research highlights the need for specialized education for researchers in the field. Technical knowledge ranges from basic microbiology disciplines, microbial ecology, human health, translational research, towards practical training in interdisciplinary teams. Beyond the technical disciplines, the integration of fundamental twenty-first-century skills is also critical to ensure collaboration, boundary-crossing, creativity and innovation Successful models of translational research education in other medical specialties provide useful guidance and structural frameworks for the development of similar programmes within the human gut microbiome field [101, 102]. Valuable lessons can be learned from the Eureka Institute for Translational Medicine (https://eurekainstitute.org/), which delivers intensive training programmes for early- and mid-career researchers in medical disciplines, including the Eureka International Summer Course on Translational Medicine and the Master of International Translational Medicine. Other comprehensive programmes, such as the BRIDGE—Translational Excellence Programme, offer two-year postdoctoral training in translational medicine, encompassing education, research, and mentoring (https://bridge.ku.dk/about/). Together towards effective translation: joint efforts and expertise Even with the implementation of education specifically tailored to translational human gut microbiome research, the complexity of the translational process makes it highly challenging for a single individual to achieve expertise across all its phases [100]. Therefore, successful human gut microbiome research requires the convergence of diverse expertise within interdisciplinary teams [98]. Interdisciplinary research teams in human gut microbiome research are envisioned to include translational human gut microbiome researchers, as well as experts from relevant fields such as nutrition, medicine, food technology, and data analysis, among others, depending on the study focus. In line with principles of translational medical research, these teams may also engage stakeholders as co-creators, for example, healthcare professionals, patients, members of society, policymakers, and industry representatives [32, 63, 103]. An exceptional example of interdisciplinary collaboration driving successful translational outcomes is the “lightspeed” approach developed during the COVID-19 pandemic [26]. This framework accelerated vaccine and therapeutic development by integrating academia, industry, clinicians, regulators, and manufacturing partners within highly coordinated research systems. Key elements included conducting clinical, regulatory, manufacturing, and operational processes in parallel, real-time data sharing, simplified regulatory procedures, flexible trial designs that could be modified as new evidence emerged, and large-scale infrastructure investment, enabling the development and deployment of COVID-19 interventions within unprecedented timelines. These coordinated efforts demonstrated how integrated translational frameworks can rapidly transform scientific discoveries into real-world clinical applications. In human gut microbiome research, similar principles could improve scalability and translational impact through harmonized multi-site infrastructures, standardized metadata collection, coordinated clinical and computational workflows, and real-time data sharing. This model illustrates how coordinated interdisciplinary research combined with stakeholder engagement can help address persistent challenges in human gut microbiome research, including fragmentation, limited reproducibility, and slow clinical translation. Improving the connection between research and healthcare Meaningful stakeholder engagement can be encouraged in all phases of translational medical research, encompassing a bi-directional relationship between the stakeholder and researcher that offers real opportunities for informed decision-making about the design of studies, including the identification of an unmet health need, the development of research questions, the conduct of research, data collection and analysis, as well as after research is concluded to ensure uptake and adoption of the results [49, 104]. To date, however, most of the attention has been focused on engagement in the latter stages of translational research, particularly in clinical validation (T2), clinical translation (T3), and in public health (T4). Comparatively, little is reported about stakeholder engagement in the earliest stages of translational research (T0–T1), which are focused on developing and testing new concepts and models – devices, diagnostics, therapies, drugs, or data algorithms [63] In particular, researchers working in the T0 phase (basic and preclinical research) often have limited direct interaction with real-world settings. Their work is typically laboratory-based, with restricted involvement in interdisciplinary teams and minimal engagement with stakeholders beyond their immediate research scope. Strengthening connections among basic/preclinical researchers and healthcare professionals, patients, and society is considered critical to ensure a bidirectional knowledge flow across T0–T4 [105]. Such engagement can enhance awareness of unmet health needs, including their severity and urgency, and support the integration of diverse perspectives across all phases of translational research [103]. This, in turn, fosters a shared, problem-solving approach to address these needs (Fig. 3). Successful integration requires equal openness and commitment from both the research and healthcare systems. Strengthening the connection between research and healthcare systems Effective translation of knowledge from bench to bedside requires continuous integration between researchers and the healthcare system across clinical and public health settings. This depends on sustained interdisciplinary collaboration, structured communication, and coordinated knowledge exchange among researchers, healthcare professionals, patients, and society representatives. Engaging patients and society as active stakeholders throughout the research and implementation process ensures relevance, applicability, and alignment with real-world healthcare needs. Several mechanisms can be decisive for effective participatory research involving stakeholders: beyond identifying a shared interest, investing in personal relationships and building mutual trust, seems to foster a collaboration that creates value for all the involved stakeholders [106]. Additionally, the involvement of stakeholders in research requires important ethical considerations, including relational and moral complexities concerning collaboration, sharing power, as well as democratic and transparent decision-making [22]. Patient-centric research Conventionally, patients are included in clinical research as participants under intervention or observation, becoming just a statistical number without active involvement in the development of the study design, research questions and interpretation of the results [107]. In recent years, it has become increasingly recognized that translational medical research is most effective when patients, the key stakeholders whose health can be directly affected by research outcomes, are actively engaged [108]. In line with that, patient-centric approaches have emerged, in which research starts from patients, engages them, and keeps them at the centre at all levels [41, 42]. Remarkably, the revised Declaration of Helsinki (2024) [109] places great emphasis on patient involvement as partners in research, proposing a shift in the traditional terminology, from human “subjects” to “participants” [110]. Patient-centric research has also been highlighted as one of the most important aspects in the context of next-generation evidence-based medicine [66, 111]. Incorporating patient perspectives into the research workforce, addressing their unmet health needs, and considering the reported impact of studies on their well-being can drive meaningful advances in medical discoveries [112, 113]. Patients hold information that healthcare professionals and researchers do not have: a uniquely extensive personal database of how a particular disease can affect their lifestyle, routine, mind and body at the individual level [45]. Ultimately, patients offer a critical and often underrepresented knowledge as lived-experience experts, having directly navigated the conditions under study, sometimes for years or a lifetime, while undergoing various treatments with associated side effects and limitations [114]. Patient-centric research approaches have been proposed across several medical fields, including cancer [25, 108], immune-mediated diseases [115], cardiovascular diseases [24, 116], and type 2 diabetes [117]. A highly relevant example of patient-centric implementation in oncology is the PRO-TECT trial, a randomized clinical study of over 1.100 patients with metastatic cancer that integrated real-time electronic patient-reported symptom monitoring into routine care over the course of treatment [25]. Patients provided weekly electronic symptom reports, which triggered automated alerts to clinicians when symptoms worsened, creating a real-time feedback loop between patients and oncology teams. These patient-reported outcomes were incorporated into clinical decision-making through a remote longitudinal data collection system with minimal participant burden across treatment cycles. This approach enabled continuous data capture and sustained patient engagement over extended follow-up, resulting in improved survival and quality of life outcomes. Overall, the trial demonstrates how incorporating structured patient participation into clinical workflows can enhance both data completeness and clinical impact. The Heartline Study provides another useful example of how participant engagement strategies can improve adherence and feasibility in long-term real-world research. In this fully remote study involving more than 30.000 older adults, engagement was supported through participant-centric app design, behavioural nudges, reminders, simplified onboarding, continuous technical support, and regular communication tailored to participant needs [24]. These strategies enabled sustained engagement over a two-year follow-up period, with high rates of app use, survey completion, and retention despite the decentralized design. The study highlighted that proactive engagement infrastructure was essential for maintaining longitudinal data completeness and protocol adherence in real-world settings [118]. These insights are highly relevant to human gut microbiome research, where longitudinal sampling, repeated faecal samples collection, dietary logging, and metadata completeness are major challenges. In contrast to other medical fields, where patient-centric research is increasingly recognized and implemented, current evidence suggests that patient-centric research design is still limited in human gut microbiome research [119]. Notably, human gut microbiome research is especially suited for deep patient involvement: gut microbiome health is strongly influenced by behavioural factors such as diet, exercise, sleep patterns, stress, and lifestyle overall, which are largely under patient control [120, 121]. This makes patients not just participants, but valuable co-creators in shaping research questions that are personally meaningful and clinically relevant [115]. For example, rather than primarily focusing on gut microbiota alterations and generic inquiries, studies can incorporate patient-driven questions such as: “Which dietary changes most effectively improve my symptoms?” In studies requiring repeated sampling (for example, blood or faecal samples), anthropometric measurements, or longitudinal questionnaire data, co-designing protocols with patients is a promising strategy to enhance feasibility, adherence, and data quality [24]. Patients can provide practical insights into what is manageable in daily life, helping to reduce participant burden and dropout. Patient-centric approaches can include simplified sampling workflows, digital reminders, feedback dashboards, and educational activities. Additionally, involving patients in defining meaningful endpoints ensures that research outcomes reflect real-world priorities, such as symptom relief, quality of life, and functional improvement [116, 117]. For instance, patients may determine: “What outcomes are the most important to me: symptom reduction, energy levels, or quality of life?”, or “How can research findings be translated into practical recommendations I can use?” Their perspectives can also guide interpretation of findings and inform the direction of future research, ultimately increasing the likelihood of clinical impact and implementation. Beyond isolated frameworks for single studies, structured and collaborative platforms provide the support and expertise required to advance patient-centric research across medical fields. A prominent example is the European Patients’ Academy on Therapeutic Innovation (EUPATI - https://eupati.eu/). This platform focuses on educating, empowering, and integrating patients into all phases of translational research. By providing training and resources, it supports meaningful collaboration between patients and researchers, helping to bridge knowledge gaps and promote shared decision-making in therapeutic development. From unmet health needs to research gaps In translational medical research, the primary aim is to address unmet health needs at the clinical, population, and societal levels. Naturally, identifying these needs requires structured approaches, including engagement with patients, populations, and society—essential also at this stage to ensure both translational relevance and feasibility [41, 64]. Subsequent to identifying an unmet health need, defining an area of interest for medical research involves a systematic assessment of existing evidence to identify research gaps, including knowledge, implementation, and refinement gaps [122]. This is achieved through a systematic review of the literature, which maps current protocols, evidence-based therapies, diagnostic tools, medical products, and clinical guidelines, in order to characterise what is already known and where uncertainties or limitations remain [123]. From this perspective, the identification of research gaps must be systematically aligned with unmet health needs. In the context of the human gut microbiome, the question “what is already known?” poses a challenge in face of the huge amount of data generated in the field, particularly over the past two decades [124, 125]. Beyond that, which studies have demonstrated causality [6, 16]? In addition, it is important to consider whether identified gaps present opportunities for the development of gut microbiome-based or gut microbiome-targeted therapies [1]. How to identify these human gut microbiome research gaps? Questions arise regarding the clinical relevance of current findings: Are there microbiome-based biomarkers of health and disease? [57, 68] Are there evidence-based interventions that effectively modulate the gut microbiome to improve health outcomes? [3, 9] Which existing therapies, such as probiotics, prebiotics, dietary interventions, or faecal microbiota transplantation, have demonstrated efficacy, and what are their limitations? [5] Importantly, research gaps in human gut microbiome research may also relate to incomplete mechanistic insights, limited longitudinal data, inconsistent or contradictory results across studies and non-validated methods [16, 17]. Due to the intricacy of the human gut microbiome, translational research questions in this field are inherently more complex than in many other medical disciplines. Consequently, rather than being explicitly driven by an identified unmet clinical need or a predefined research gap, several human microbiome studies have adopted an exploratory perturbation–response approach [70]. In these designs, the gut ecosystem is intentionally perturbed in otherwise healthy individuals using interventions such as antibiotics, probiotics, prebiotics, or dietary modifications, applied either in vitro or in clinical study settings [126–128]. The primary objective is not therapeutic evaluation, but rather the characterization of system-level responses, including changes in gut microbiota composition and functions, as well as ecological resilience following controlled perturbation [9]. While such studies can provide fundamental insights into microbiome dynamics, their direct translational relevance is often limited, and the ethical implications of deliberately inducing biological perturbations in healthy participants remain a subject of ongoing discussion. Human gut microbiome literature: finding a needle in a haystack As the human gut microbiome has gained central focus in medical research, a major challenge is effectively navigating the rapidly expanding body of literature and large-scale public datasets. Over the past two decades, studies on the human gut microbiome have increased exponentially, reflected in a rapidly growing publication output, yet this expansion has not been accompanied by corresponding translational outcomes. In order to illustrate this trend, we performed a PubMed search (21 April 2026) using the query: ‘human gut microbiome’ OR ‘human gut microbiota’ OR ‘human intestinal microbiome’ OR ‘human intestinal microbiota’ OR ‘human gut flora’ OR ‘human intestinal flora’, all fields, which resulted in a total of 83.783 publications. Adding the word ‘translational’ to each term in the query resulted in a much lower number of publications, a total of 7.148 (Supplementary Figure 1). Although the number of publications addressing translation in human gut microbiome research remains relatively limited, it has shown a clear upward trend in recent years. Our simplified search was conducted primarily to illustrate the dimension of this discrepancy. However, our approach has inherent limitations: relevant studies that did not explicitly reference translation may have been excluded, while others referring to the biological process of RNA-to-protein translation may have been inadvertently included. Identifying relevant studies on the human gut microbiome can be overwhelming and misleading, given the vast number of publications produced annually. It is not feasible for individual researchers to comprehensively review this expanding literature, which can influence the selection of references used in new studies, increasing the risk of prioritizing citations from high-impact journals or from within established academic networks [129]. Although artificial intelligence tools, such as ChatGPT, Google Gemini, and Microsoft Copilot, have been developed and can offer support for literature selection, their use also raises important ethical considerations related to bias, transparency, reliability, and accountability [130, 131]. In addition to the challenges described above, publication delays can hinder the translation of findings, highlighting the need for more efficient publication processes and policies that support early dissemination through preprints. In this context, “open science” has gained increasing attention in the medical field as an approach that promotes equitable access to clinical data, protocols, and results [132]. Such practice may facilitate transparency, reproducibility, and progress in translational human gut microbiome research at a global scale [100]. Beyond literature selection, refining hypothesis formulation, promoting the publication of negative findings, and ensuring transparent reporting of study limitations are critical for improving research quality and reliability, as well as reducing publication bias [133]. Importantly, valuable research contributions are not limited to hypothesis confirmation or rejection but also include the generation of new ideas and perspectives, novel research questions, and methodological advances. Furthermore, the promise of the human gut microbiome for the development of new therapies, diagnostics, and interventions has attracted researchers from diverse disciplines, including many with limited formal training in the field. This lack of specialised education in human gut microbiome research, together with sustained pressure to publish, may contribute to an increase in studies of limited translational relevance. However, this problem is not unique to human gut microbiome research, as the broader medical literature is experiencing a rapid rise in unreliable publications, contributing to the “replication crisis”, also believed to delay and complicate translational progress [134]. How serendipity can shape translational research While identifying unmet health needs and research gaps can be considered a fundamental pillar of translational research, it is important to acknowledge that unpredictable findings relevant for effective translation can happen along the process of any research phase. It has been recognized that filling a translational pipeline with new findings requires a certain degree of serendipity in fundamental biomedical research, in addition to “planned” discoveries [135]. One of the best examples of serendipity leading to new, groundbreaking discoveries in microbiological research is probably the discovery of penicillin made by Alexander Fleming in the mid-20th century [136]. Methods for human gut microbiome research Human gut microbiome research currently presents limited well-established, standardized, and validated methods for both laboratory experimentation and data analysis, partly due to its relatively recent and rapidly evolving nature [4, 14]. Combined with the inherent complexity of the gut microbiome, this poses significant challenges to reproducibility, as studies frequently produce inconsistent or conflicting findings [137]. Specifically, an important contributing factor is the high microbial diversity of the gut microbiome, which facilitates the generation of large datasets, either through direct sequencing of DNA from faecal samples in clinical studies or by using faecal samples as inoculum in in vitro experiments [138]. These extensive datasets require careful interpretation, as the use of complex data and elaborate graphical representations can create a perception of increased relevance that is not necessarily supported by the underlying findings [139]. Given the central role of faecal samples in human gut microbiome research, the optimization, validation, and standardization of protocols for their collection, processing, and analysis represent a key methodological priority in the field [140]. How well these faecal samples represent the content of the gastrointestinal tract is still debated, since significant differences in microbial composition were found when analysing its different sites, particularly duodenum, ileum, as well as proximal, transverse and distal colon [141]. Particular points for consideration are temperature and duration of storage from collection until further processing, type of buffer, cryopreservation, homogenization, filtration, and, among others, pooling several faecal samples from different individuals as inoculum [142]. Overall, many attempts have been made to standardize those methods, contributing to a surge of several ‘optimal protocols’, without a consensus in the literature [17, 143]. Ethical considerations are fundamental even for non-invasive collection of faecal samples. Besides the approval of studies by ethical committees, this includes the care and attention provided for the patients in every step of the process. Clear instructions, provision of materials, confidentiality and information about study results, facilitate the participation of patients and contribute to the success of microbiome research and clinical applications [119, 144]. The methodological challenges in human gut microbiome research extend well beyond faecal samples, which are used here as a representative example. This review does not aim to provide an exhaustive overview of all methods applied in the field. Instead, the limitations of current approaches, as well as proposed improvements, have been extensively addressed in previous publications [14, 17, 145, 146]. T0: Basic research & preclinical studies Subsequent to the identification of an unmet health need and a corresponding knowledge gap, basic research and preclinical studies provide the foundation for exploring potential interventions and generating critical evidence to inform later clinical research [16]. More specifically, basic research and preclinical studies (T0) of the human gut microbiota include in vitro fermentations, organoids, gut-on-a-chip systems and animals models, which have been extensively applied in the investigation of fundamental aspects of microbial ecology, host–microbe interactions, and mechanistic pathways that underlie human health and disease [147]. In vitro fermentations allow for the assessment of microbial growth dynamics, substrate utilization, metabolite production and microbial interactions, and have been extensively applied to study the effects of nutrients and drugs on the gut microbiota [148, 149]. Organoid and gut-on-a-chip models provide opportunities to study the complex crosstalk between the microbiota and intestinal epithelium, including barrier function, inflammation, and nutrient absorption [150, 151]. Animal models, for instance, facilitate the evaluation of systemic effects of gut microbiome on metabolism, physiology, and the development of diseases, allowing for controlled manipulation of microbial communities and the testing of microbiome-targeted interventions in the full complexity of the gut microbiome ecosystem [152]. Collectively, these approaches can provide critical mechanistic insights that precede and complement clinical research, contributing to the theoretical and empirical foundation necessary to advance translational human gut microbiome research [153]. In addition, T0 studies of the human gut microbiota extend beyond the investigation of microbial perturbations, potential therapies, and experimental interventions. They also encompass efforts to develop new protocols, as well as validate, optimize and standardize experimental models, evaluate methodological reproducibility, and critically assess existing protocols through meta-research [143, 154, 155]. Such studies are critical to ensure the robustness, reliability, and interpretability of findings, thereby also providing a solid foundation for the design of clinical studies [4]. By integrating mechanistic exploration with methodological refinement, basic and preclinical research not only advance fundamental understanding but also establish the quality standards necessary for the effective and evidence-based translation of human gut microbiome research at the clinical and societal levels [49, 131]. T1 & T2 clinical research: Phases I, II, III Clinical studies are central to translational medical research, bridging the gap between discovery and real-world healthcare impact. Experimental studies, particularly randomized controlled trials, play a pivotal role by establishing causal relationships between interventions and outcomes and demonstrating efficacy and safety under controlled conditions, thereby providing the rigorous evidence needed for regulatory approval, clinical guidelines, and adoption into practice [66, 111]. Randomised controlled trials are considered the gold standard in clinical research, as randomisation minimizes selection and confounding biases, while prospective protocols with strict inclusion and exclusion criteria, well-defined interventions, and predefined endpoints ensure rigor and reproducibility [156]. Figure 4 presents an algorithm of types of clinical research, adapted from the literature [157]. Types of clinical research. Clinical studies can be categorized in two major groups: experimental and observational. On the left side, experimental studies are at the core of translational medical research, allowing to determine the effects of interventions. For example, in the context of gut microbiome-targeted studies, interventions include testing diets, dietary components, prebiotics, probiotics, symbiotics, phage therapy, postbiotics, FMT or drugs, either in patients or populations. Randomized controlled trials are considered the golden standard of clinical research, comparing the newly proposed treatment to either placebo or a standard treatment, reducing bias. On the right side, observational studies, which support the identification of unmet health needs and potential targets for experimental research. Algorithm adapted from the literature [157] In contrast, observational studies, including prospective and retrospective cohort studies, case-control studies, and cross-sectional studies, contribute by identifying unmet health needs, characterizing disease burden, and generating hypotheses that inform the design of experimental studies [158, 159]. They also extend translation into the real world by evaluating effectiveness, safety, and implementation across diverse populations and routine clinical settings, while presenting a limited ability to establish causality compared to randomized trials, being more prone to confounding and bias [160]. Together, experimental and observational studies are complementary approaches that ensure that innovations are not only methodically valid but also relevant, scalable, and impactful in addressing real-world health challenges [161]. Clinical studies within the context of translational medical research are divided into three phases, as presented in Table 2/A. Proof-of-concept studies (T1 – Clinical Phase I) are typically conducted following basic and preclinical research to evaluate whether an intervention demonstrates an initial biological or clinical signal in humans [8, 86]. Subsequently, pilot trials (T2 – Clinical Phase II) are designed to assess the feasibility of study procedures, including recruitment, implementation, and outcome assessment, prior to a larger clinical study, particularly randomized controlled trials (T2 – Clinical Phase III) [87, 92, 162]. Both proof-of-concept and pilot studies are generally short in duration and limited in scale, with the literature commonly reporting sample sizes ranging from 20 to 100 participants. This small-scale design aligns with ethical considerations discussed in first-in-human research, where minimizing participant exposure to uncertain risks is prioritized before broader clinical validation and implementation [163]. Phase III clinical trials (T2) represent a critical stage in the development of new interventions, aimed at confirming efficacy, monitoring adverse reactions, and comparing the investigational treatment with standard care or placebo [95]. These studies are typically randomized and controlled, minimizing bias and enabling robust evaluation of treatment effects in large patient populations, ranging from several hundred to several thousand participants, and are conducted across multiple centres to ensure diversity and generalizability of findings [94]. Their scale and methodological rigor allow for comprehensive assessment of both effectiveness and safety, providing the key evidence required for regulatory approval and clinical implementation [37]. A remaining question is where observational studies fit within the translational research phases (Table 2/A). Given that they primarily identify associations rather than causal relationships, they are most useful for informing the design of interventional studies (T1 & T2 - Clinical phases I, II, III). As such, they may be best positioned at the interface between T0 (basic research and preclinical studies) and T1 (translation to humans) phases. In practice, the established conceptual translational framework for the classification of clinical studies is not consistently used in reporting, as relatively few studies are explicitly described as proof-of-concept or pilot trials [164]. Particularly in human gut microbiome research, small clinical studies are frequently misclassified, with proof-of-concept or pilot studies commonly reported as “clinical trials” without acknowledgement of their preliminary exploratory or feasibility nature [8]. As a result, the absence of standardized nomenclature makes it difficult to contextualize findings, assess study maturity, improve interpretation of their clinical significance, and determine their relevance within the translational process [165]. Furthermore, determining causality has been one of the major challenges in human gut microbiome research, which limits the evidence required for effective translation [6]. Causal inference is particularly limited by extensive, interdependent confounding that affects both microbial composition and host outcomes [4]. Factors such as diet, drugs, age, genetics, lifestyle, and environment can shape the microbiome while also correlating with disease, making it difficult to distinguish cause from association in clinical studies [131, 158]. At the design level, confounding is primarily addressed through randomization in intervention studies, particularly randomized controlled trials supporting the balance between both measured and unmeasured confounders across study arms [160]. Standardization of sampling protocols and comprehensive metadata collection are also essential to ensure consistent capture of key covariates, including diet, medication use, lifestyle, and clinical history, thereby enabling more accurate adjustment in downstream analyses [166]. Longitudinal sampling further strengthens inference by enabling within-subject comparisons over time, which inherently control for stable host factors such as genetics [167]. In addition, patient engagement in study design can improve protocol adherence, data completeness, and overall feasibility, thereby strengthening data quality and reducing potential sources of bias, particularly in real-world and long-term studies [24]. At the analysis level, multivariable regression, mixed-effects models, and causal inference approaches such as propensity score methods, inverse probability weighting, and causal discovery frameworks are commonly used to adjust for observed confounders [168]. Specifically for biomarker research, applying the concepts from the biomarker validation frameworks (Table 1) supports the progression of research through T0–T4, ensuring analytical validity, clinical validity and clinical utility, as well as that ethical, legal and social implications are taken into consideration [29]. Biomarker validation frameworks are structured approaches used to assess the strength and maturity of evidence supporting a biomarker across the translational research continuum (T0–T3), and to determine whether it is sufficiently validated to justify progression into later-stage clinical validation and ultimately implementation [30]. Within this continuum, they provide a systematic way to evaluate the level of evidence generated in preclinical and early clinical studies, with particular emphasis in the T2 phase, where candidate biomarkers identified in earlier stages are tested in independent human cohorts to assess reproducibility and clinical validity, including their predictive or prognostic performance. Clinical validity refers to the ability of a microbiome-derived signal, such as taxonomic signatures, diversity metrics, functional profiles, or microbiome-based classifiers, to reproducibly associate with clinically meaningful outcomes, including disease presence, prognosis, or treatment response [3, 169]. For instance, high inter-individual variability, strong confounding, limited causal inference, and methodological variability collectively challenge the establishment of clinical validity in human gut microbiome research [68]. From population to personalization Compared with many established medical fields such as cardiovascular or immune diseases, where inter-individual variability can often be captured through well-defined risk factors or clinical subgroups, the human gut microbiome exhibits substantially higher and more complex variability [10, 11, 170]. The human gut microbiome is highly individual-specific and shaped by a unique combination of genetic, environmental, dietary, and lifestyle factors, resulting in substantial inter-individual variability and the absence of a universally defined “healthy” baseline [12, 13]. Consequently, only limited broadly applicable conclusions can be derived from population-level studies, which helps explain the slower and more complex translation of microbiome research into clinical and public health applications, often requiring more tailored, data-driven approaches [171]. A persistent dilemma in human gut microbiome research lies in aligning population-level representativity with individual specificity. On one hand, there is a clear need to increase the representativeness of study populations in terms of age, gender, geography and cultural traditions, to discover features of gut microbiomes that are unique to different locations and lifestyles [172–174]. Diversity, equity and inclusion are critical for generating findings that can be translated into broadly applicable public health guidelines and nutritional recommendations, which are typically derived from population averages [65]. On the other hand, the composition and functional characteristics of the human gut microbiome are highly individualized, which challenges the effectiveness of “one-size-fits-all” interventions and highlights the need for personalized approaches in clinical applications [69]. Evidence-based clinical translation in the gut microbiome depends on individual-level data, requiring studies that move beyond group averages to generate predictive models integrating microbiome, host, and environmental factors [69, 175]. Accordingly, precision medicine promises the stratification of patient heterogeneity using predictive biomarkers of response to guide therapeutic decisions, thereby minimizing ineffective treatments and adverse effects [161, 176]. From a future healthcare perspective, the integration of personalized data, including human gut microbiome profiles, dietary intake, genomic data, and relevant biomarkers, will be facilitated by digital technologies and increasingly supported by artificial intelligence, enabling the development of more precise and targeted interventions, which is also in alignment with patient-centric research [23, 28, 130]. A remaining implementation gap in human gut microbiome research is the translation of complex omics-based and computational approaches into streamlined, user-friendly tools suitable for routine clinical practice, which will be essential for their effective integration into everyday healthcare use [177]. How strong is the evidence? Effective translation is only achievable when high-level evidence (see evidence levels in Table 1) is available to support the safety, efficacy, and real-world applicability of interventions, as well as their relevance to individual patients in the context of personalised care. Evidence-based translation typically relies on systematic reviews and meta-analyses to establish the strength of evidence for clinical and population-level applications. By integrating data across studies, meta-analyses enhance statistical power, identify consistent and reproducible signals, and support the selection of interventions with greater generalizability across diverse cohorts [178]. However, their validity depends on the quality, methodological comparability, and careful consideration of confounding factors across individual studies. This highlights the need for well-designed and rigorously conducted clinical and epidemiological studies in human gut microbiome research, as discussed in the previous sections. A strong body of evidence will provide the necessary foundation for informed decision-making in clinical practice, enabling interventions to be adapted to patient-specific characteristics, preferences, and risk profiles, while also ensuring robust application at the population level. T3 & T4: Effective translation for patients, populations, and society Ultimately, all phases of translational medical research aim to achieve meaningful impact by ensuring that discoveries are effectively applied, whether in clinical settings to improve patient care, or at the population and societal levels to reduce disease burden, address health inequities, and inform public health strategies and policies [36, 49]. Clinical translation (T3) consists of the successful achievement of the “from bench to bedside” approach adopted in translational medical research, when interventions are approved after the clinical trial phases and implemented effectively into practice. Clinical translation relies on solid and robust data for evidence-based practice, in which new therapies, diagnostics, tools and clinical guidelines are integrated into the health system and adopted by trained healthcare professionals for individualized patient care [175, 179]. Essentially, evidence-based practice within the patient-centric approach requires integrating the best research evidence with clinical expertise, incorporating the values and preferences of the patient, in a shared decision-making process [33]. In human gut microbiome research, the most successful clinical translation to date is FMT for the treatment of recurrent C. difficile infection (Table 2-B), which is not only included in clinical guidelines but also extensively adopted in clinical practice [71, 76]. Translation to society (T4) is the latest phase of translational medical research, moving beyond clinical settings to public health, encompassing epidemiology, nutrition, chronic disease, and global and environmental health; entrepreneurship and technology transfer; and educational curricula [19]. This phase includes strategies focused on prevention, such as public health policies, screening programs, nutrition and lifestyle recommendations, and also the approval of new food products, such as nutritional supplements, considered safe for consumption by the general population [123, 180]. Notably, successful examples of translation to society from human gut microbiome research include inulin (a prebiotic), L. rhamnosus (a probiotic), and pasteurised A. muciniphila (a postbiotic), which have been approved by the EFSA for population-level consumption, however without endorsement in health guidelines or reported extensive adoption by society (Table 2 -B) [83, 88, 93]. Although a growing number of studies have evidenced the pivotal role of diet in shaping human gut microbiome for health or disease, microbiome-based recommendations for the population have not yet been incorporated in dietary guidelines [1, 72, 97, 121]. Dietary guidelines represent a fundamental pillar of nutrition policies, translating scientific evidence into clear and actionable recommendations for populational healthy eating informing public health campaigns, school meal standards, and food regulations [181, 182]. These guidelines could be enriched, for example, by incorporating recommendations on the diversity and types of dietary fibre, not only their total quantity, supported by emerging evidence and translated into practical guidance [183]. The current recommendation of 25 grams of dietary fibre per day for adults, was established by EFSA based on maintaining regular gastrointestinal function [184]. Historically, the benefits of dietary fibre were not associated with its fermentation by the gut microbiota, which was only evidenced by later studies [2, 121]. Societal factors such as industrialized diets, antibiotic use, and cultural practices have been linked to adverse health outcomes, partly through their effects on the gut microbiome [185]. Gut microbiome-based health strategies have the potential to support all areas of healthcare, including prevention, precision medicine, participation, personalisation, and population health [19]. Active engagement of stakeholders from society in this phase ensures that preventive health measures are not just systematically accurate, but also practical, inclusive, trusted, and effective in real-world settings [22, 106]. A critical translational barrier in human gut microbiome research is the limited evidence available to support effective translation and implementation in T3 (clinical translation) and T4 (society translation) [3, 20, 44]. In addition, regulatory uncertainty remains an important challenge, as frameworks for microbiome-based or -targeted interventions, biomarkers, and diagnostic tools are still evolving [15]. Importantly, regulatory frameworks typically evolve in parallel to evidence demonstrating safety, efficacy, reproducibility, and clinical utility [36]. Considering the current status of translational human gut microbiome research, it remains premature to prioritize regulatory harmonization before a stronger and more robust evidence base has been established [1, 5]. Therefore, the immediate priority for effective translation is to strengthen the generation of high-quality evidence capable of supporting credible clinical application, broader societal and public health implementation, and future regulatory alignment. Building blocks of translational human gut microbiome research Effective translation is achieved when the earliest phases of translational research have been successful [61, 62]. However, basic research and preclinical studies (T0) are often perceived as dissociated from translation, since this early phase is somehow distant from application. As discussed previously in this review, translational development relies on the progress of T0, followed by the clinical validation phases (T1–T2), and ultimately the later phases, consisting of effective translation to patients (T3) and society (T4). For that, building a solid foundation with consistent and reliable studies is a promising strategy, considering basic and preclinical research the fundamental pillars of research. Organizing the knowledge about human gut microbiome in the form of building blocks may assist in adopting this perspective (Fig. 5). Trapped in a spiral of information versus building knowledge for translation. A. Not surprisingly, in the midst of an avalanche of information, gut microbiome researchers are often found overwhelmed with countless remaining questions. A situation illustrated by a spiral of information, spinning around, ready to be disentangled and pushed forward. B. On the other side, as soon as the translational research phases are put into perspective, all the knowledge built in the gut microbiome field can be organized as building blocks for translation. In this light, previous relevant studies can be selected as a foundation, allowing targeted, problem-solving, patient-centric approaches to flourish, bringing the long-awaited answers on how to successfully develop, validate and implement human gut microbiome modulation of human health. At the same time, new studies can be designed in agreement with all those principles Time for action: A framework for human gut microbiome translation A central priority in advancing translational human gut microbiome research is the establishment of a strong foundational framework that precedes and enables effective translational execution. This starts with the development and implementation of targeted education programs to shift researcher mindsets toward patient-centric, impact-driven approaches and to foster a solid understanding of translational principles. Building on this foundation, the formation of interdisciplinary research teams and the active integration of key stakeholders—including healthcare professionals, patients, industry, and policymakers—are essential to ensure relevance and applicability. In parallel, systematic identification of unmet health needs and critical research gaps should guide the formulation of meaningful research questions in the context of translation. This is followed by an evaluation of whether human gut microbiome research can provide novel or improved approaches compared to existing standard strategies. If the unmet health need falls outside the scope of human gut microbiome research, it is not pursued further within this research framework. Equally important is the optimization, validation, and standardization of research methods, supported by open platforms for protocol sharing and critical discussion to enhance reproducibility and transparency. Together, these foundational priorities create the conditions necessary for the effective progression through the translational research phases (T0–T4), ultimately bridging fundamental microbiome research with clinical and societal application. Figure 6 presents a synthesizing conceptual framework derived from the preceding sections in this paper, integrating education, interdisciplinary team building, stakeholder engagement, patient-centric approaches, prioritization of unmet health needs, and methodological standardization as key enablers of translational progression in human gut microbiome research. Framework for translational human gut microbiome research. This is a synthesising conceptual framework to be further refined and validated. Priorities are presented from top to bottom. As a foundation for successful translation in human gut microbiome research, we highlight the requirement for targeted education, incorporation of translational principles and methodological standardisation as key enablers of translational progression through T0 – T4 We acknowledge that a key limitation of this proposed framework is the absence of direct interdisciplinary co-development and stakeholder involvement, which are essential components of mature translational and patient-centric research and may be incorporated in future refinement and empirical validation. Advancing human gut microbiome translation: Final perspectives Human gut microbiome research has made substantial progress in the early stages of translational research, particularly in T0 (basic research and preclinical studies), T1 (translation to humans: proof-of-concept studies) and T2/II (validation: pilot clinical studies), while progressively moving toward the later clinical phase T2/III (validation: larger clinical studies). However, translation toward T3 (clinical translation) and T4 (society translation) remains limited, with only emerging and context-specific examples rather than extensive application and implementation. The integrative scope of this review has provided important perspectives on translation in human gut microbiome research and allowed us to identify several major missing pieces of the puzzle for advancing translational progress in the field. Firstly, we conclude that a priority area requiring development is the education and training of translational human gut microbiome researchers, which will facilitate the incorporation of translational medical research principles into the field. Secondly, the establishment of interdisciplinary teams, active stakeholder engagement, and the adoption of patient-centric approaches will allow the connection of research and healthcare and joint efforts toward advancing translation for human health. In parallel, there is a need to better identify unmet health needs, determine whether these align with current research gaps, and evaluate whether they can realistically be addressed through human gut microbiome research. Furthermore, it is clear that advancing translation toward effective implementation will require substantial improvements in the level of evidence generated within human gut microbiome research. A remaining challenge for the field is determining how this evidence can be strengthened. Beyond the key missing elements discussed above, we believe that progress will depend on the development of standardized and validated platforms and protocols, together with greater rigor in study design and stronger integration across the translational process (T0–T4), in which each phase informs and strengthens the next. Collectively, these approaches will contribute to building a more consistent, reliable, and solid foundation upon which effective translation will be achieved. Finally, moving human gut microbiome research out of the comfort zone, facing all the challenges and integrating the principles of translational medical research, is a step necessary for more successful applications to improve human health. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Acknowledgements We would like to express our sincere appreciation to the Eureka Institute for Translational Medicine for the inspiration, creative ideas, and invaluable support in the conceptualization and initial development of this work. We are particularly grateful to Professor Berent Prakken for his genuine willingness to share his knowledge and expertise, for his insightful review of this work, for his exceptional guidance on translational medical research, and for setting a brilliant example of leadership and humanity in education and research. Author contributions Marina Fassarella conceptualized and wrote the manuscript, searched literature, created the figures, graph and tables, revised all the versions of the manuscript. Hauke Smidt revised the manuscript critically for important intellectual content, particularly on the content related to the human gut microbiome. Funding This work was conducted in parallel to the official PhD project of Marina Fassarella, supervised by Hauke Smidt, and supported by the CarboBiotics consortium (project number ALWCC.2017.003). The consortium was coordinated and funded by the Dutch Research Council (NWO) and the Carbohydrate Competence Center (CCC), in collaboration with industrial partners Avebe, FrieslandCampina, Nutrition Sciences, and TKI Agri & Food. The funders had no role in the conceptualisation, design, writing, or content of this work, nor in the decision to submit it for publication. Data availability Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Consent for publication All authors read and approved the final version of the manuscript for publication. Author information M.F. has expertise in Human Nutrition and Microbiology, with a particular focus on Clinical Nutrition and the Human Gut Microbiome. Her extensive experience across Education, Research, and Healthcare has enabled her to integrate these domains into a strongly translational and patient-centric research perspective, driven by a deep sense of care and responsibility to address unmet health needs she has directly witnessed during her professional journey. She considers patients not as “them,” but as ourselves – our families, our friends, our colleagues, and our neighbours – in urgent need of better health solutions. Guided by empathy and compassion, she advocates for humanity in medical research and for research committed to improving the health of patients and society. H.S. has expertise in Microbial Ecology and is passionate about the role micro-organisms play in all facets of planetary health and dedicates his efforts towards deploying Microbiomes to address challenges we face regarding Human, Animal, Plant and Environmental Health. He holds a professorship in Complex Microbial Ecosystems at Wageningen University & Research, coordinates the large UNLOCK infrastructure for Microbiome Research and is Co-Chair of the Wageningen Microbiome Center. He is deeply convicted that scientific research as integral part of society can only flourish through adopting a strongly collaborative rather than competitive spirit. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.